Penpulimab vs Sintilimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Sintilimab
Marketed by Innovent Biologics and partners
NCT03607539 · Phase 3 · completed
This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.
Next expected readout: November 2026 · NCT05429463 (registry estimate)
Reported efficacy
Overall Survival (Through database cutoff date of 31-July-2020 (up to approximately 35 months)): Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). (met)
Result source: NCT03150875
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Penpulimab | Sintilimab |
|---|---|---|
| PFS, median | 8.6 vs 4.2a+4.4 vs placeboNCT03866993 | 8.9 vs 5+3.9 vs placeboNCT036075392 other results
|
| OS, median | —Not posted · NCT03866993 | 11.8 vs 8.3vs DocetaxelNCT03150875 |
| ORR | —Not posted · NCT03866993 | 51.9% vs 29.8%+22.1 vs placeboNCT036075392 other results
|
| Duration of response, median | —Not posted · NCT03866993 | 6.0 vs 5.1+1 vs placeboNCT036299251 other result
|
PFS, median
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
- Sintilimab
- 8.9 vs 5+3.9 vs placeboNCT03607539
2 other results
- 5.5 vs 4.9 NCT03629925
- 4.3 vs 2.8 NCT03150875
OS, median
- Penpulimab
- —Not posted · NCT03866993
- Sintilimab
- 11.8 vs 8.3vs DocetaxelNCT03150875
ORR
- Penpulimab
- —Not posted · NCT03866993
- Sintilimab
- 51.9% vs 29.8%+22.1 vs placeboNCT03607539
2 other results
- 44.7% vs 35.4% NCT03629925
- 25.5% vs 2.2% NCT03150875
Duration of response, median
- Penpulimab
- —Not posted · NCT03866993
- Sintilimab
- 6.0 vs 5.1+1 vs placeboNCT03629925
1 other result
- 12.4 vs 4.1 NCT03150875
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Penpulimab: 0 of 4 rows · Sintilimab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Penpulimab | Sintilimab |
|---|---|---|
| Dropout rate | — | n/a: no completion milestonea NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more resultsn/a: no completion milestone NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | — | —a NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more results— NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 — NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | — | 28.2%a NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more results38.9% NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 50.3% NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | — | a anaemia 74.1% (placebo 78.6%) neutrophil count decreased 71.1% (placebo 62.6%) white blood cell count decreased 67.7% (placebo 64.1%) NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more resultsanaemia 33.3% decreased appetite 23.6% pyrexia 21.5% NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 anaemia 93.3% (placebo 90.4%) white blood cell count decreased 88.8% (placebo 86%) neutrophil count decreased 83.2% (placebo 82%) NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sintilimab
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Sintilimab's landscape